Table 2 |
|||||||||||
|
Hemodynamic responses in baboons infused with live Escherichia coli and treated with placebo or anti-L-selectin antibody |
|||||||||||
| Time (hours) |
|||||||||||
|
|
|||||||||||
| -0.5 |
0 |
1 |
2 |
4 |
6 |
10 |
24 |
32 |
48 |
72 |
|
|
|
|||||||||||
| Heart rate (beats/minute) |
|||||||||||
| Placebo |
124 ± 3 |
125 ± 3 |
156 ± 9 |
171 ± 7 |
170 ± 5 |
160 ± 5 |
141 ± 7 |
142 ± 6 |
138 ± 9 |
139 ± 5 |
151 ± 11 |
| L-SEL-Ab |
122 ± 5 |
121 ± 4 |
160 ± 9 |
177 ± 7 |
165 ± 3 |
168 ± 6 |
151 ± 5 |
142 ± 15 |
141 ± 14 |
143 ± 10 |
158 ± 10 |
| MAP (mmHg) |
|||||||||||
| Placebo |
113 ± 6 |
122 ± 3 |
102 ± 8 |
72 ± 5 |
103 ± 5 |
117 ± 6 |
95 ± 9 |
75 ± 11 |
75 ± 6 |
65 ± 11 |
70 ± 6 |
| L-SEL-Ab |
119 ± 4 |
122 ± 3 |
104 ± 6 |
72 ± 5 |
97 ± 5 |
111 ± 6 |
85 ± 10 |
51 ± 8 |
51 ± 7 |
61 ± 12 |
79 ± 8 |
| CO (l/minute) |
|||||||||||
| Placebo |
3.1 ± 0.2 |
3.2 ± 0.2 |
4.3 ± 0.4 |
4.6 ± 0.4 |
4.4 ± 0.4 |
4.2 ± 0.4 |
2.5 ± 0.2 |
3.5 ± 0.4 |
4.2 ± 0.3 |
3.6 ± 0.3 |
3.7 ± 0.2 |
| L-SEL-Ab |
3.1 ± 3.1 |
3.1 ± 3.1 |
4.8 ± 4.8 |
5.5 ± 5.5 |
4.8 ± 4.8 |
4.6 ± 4.6 |
2.5 ± 2.5 |
3.0 ± 3.0 |
3.8 ± 3.8 |
3.6 ± 3.6 |
3.8 ± 3.8 |
| MPAP (mmHg) |
|||||||||||
| Placebo |
13 ± 1 |
14 ± 1 |
14 ± 1 |
13 ± 1 |
14 ± 2 |
18 ± 2 |
17 ± 3 |
17 ± 2 |
18 ± 3 |
15 ± 1 |
16 ± 3 |
| L-SEL-Ab |
13 ± 1 |
13 ± 1 |
13 ± 1 |
14 ± 1 |
14 ± 1 |
18 ± 1 |
16 ± 1 |
16 ± 2 |
16 ± 1 |
16 ± 1 |
15 ± 3 |
| PWP (mmHg) |
|||||||||||
| Placebo |
3.5 ± 0.4 |
3.6 ± 0.5 |
4.4 ± 0.8 |
4.5 ± 1.0 |
4.8 ± 0.9 |
5.4 ± 0.8 |
1.4 ± 0.6 |
1.5 ± 0.5 |
3.5 ± 0.3 |
2.0 ± 0.7 |
1.5 ± 1.0 |
| L-SEL-Ab |
4.6 ± 0.7 |
4.5 ± 0.6 |
4.8 ± 0.6 |
5.5 ± 0.9 |
4.6 ± 0.8 |
4.9 ± 0.8 |
2.9 ± 0.6 |
2.8 ± 0.4 |
2.7 ± 0.4 |
3.6 ± 0.9 |
3.7 ± 0.3 |
| PVR (dyn s cm-5) |
|||||||||||
| Placebo |
264 ± 21 |
258 ± 16 |
180 ± 11 |
160 ± 17 |
180 ± 20 |
265 ± 41 |
542 ± 112 |
399 ± 80 |
285 ± 58 |
292 ± 22 |
301 ± 78 |
| L-SEL-Ab |
220 ± 20 |
223 ± 18 |
142 ± 22 |
124 ± 15 |
162 ± 21 |
243 ± 30 |
441 ± 58 |
362 ± 50 |
296 ± 27 |
267 ± 25 |
279 ± 70 |
| arterial pO2 (mmHg) |
|||||||||||
| Placebo |
100.4 ± 6.8 |
101.5 ± 6.9 |
97.7 ± 5.2 |
104.8 ± 4.5 |
105.0 ± 4.3 |
100.2 ± 4.3 |
88.2 ± 2.5 |
84.7 ± 4.6 |
76.7 ± 6.4 |
73.1 ± 7.0 |
63.4 ± 6.5 |
| L-SEL-Ab |
101.9 ± 5.9 |
102.2 ± 4.4 |
105.0 ± 6.3 |
109.9 ± 4.0 |
105.9 ± 5.7 |
103.6 ± 6.0 |
91.0 ± 5.7 |
89.1 ± 5.4 |
82.2 ± 3.5 |
88.7 ± 7.5 |
77.6 ± 8.3 |
| arterial pCO2 (mmHg) |
|||||||||||
| Placebo |
48.8 ± 1.1 |
46.4 ± 1.0 |
45.0 ± 1.2 |
41.1 ± 1.2 |
34.6 ± 2.3 |
36.3 ± 0.9 |
33.2 ± 1.1 |
33.9 ± 1.9 |
34.1 ± 2.4 |
40.5 ± 3.2 |
45.7 ± 3.3 |
| L-SEL-Ab |
43.7 ± 1.5 |
43.1 ± 1.5 |
40.9 ± 0.4 |
39.1 ± 0.9 |
35.0 ± 1.7 |
34.5 ± 0.9 |
28.9 ± 2.3 |
31.5 ± 2.3 |
33.0 ± 3.4 |
35.3 ± 4.3 |
40.7 ± 6.1 |
|
|
|||||||||||
|
arterial pCO2, arterial partial carbondioxide pressure; arterial pO2, arterial partial oxygen pressure; CO, cardiac output; L-SEL-Ab, anti-L-selectin antibody; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; PWP, pulmonary arterial wedge pressure; PVR, peripheral vascular resistance. |
|||||||||||
|
Redl et al. Critical Care 2005 9:R735 doi:10.1186/cc3825 |
|||||||||||